title: Implementation of fracture liaison service in a New Zealand public hospital: Waitemata district health board experience.
abstract: OBJECTIVE
  To analyse the performance of a Fracture Liaison Service (FLS) at Waitemata District Health Board (WDHB), and to detail how systematic secondary fracture prevention can be delivered in a secondary healthcare setting in New Zealand.
  
  
  METHODS
  Clinical details of patients supervised by the WDHB FLS during the calendar year 2014 were reviewed and analysed. Additional information including treatment compliance and re-fracture rates were sought a year after initial intervention.
  
  
  RESULTS
  During the 12-month period, 301 patients with fragility fracture were seen by the WDHB FLS. All patients had clinical and laboratory assessment, one-to-one education by the FLS co-ordinator. One hundred and twenty-one patients had dual energy x-ray absorptiometry (DEXA) performed. One hundred and thirty-four of 226 treatment naive patients were started or recommended to be started on a bone protection therapy, bisphosphonate in almost all cases, and another 25 of 75 patients had adjustment made to their current therapy. Of those who were started or continued on treatment, adherence rate was 70% at a mean follow-up of 12 months.
  
  
  CONCLUSIONS
  An effective secondary fracture prevention programme, such as a FLS, can be successfully implemented in a New Zealand district hospital setting.
authors.affiliation: Department of General Medicine, Waitemata District Health Board, New Zealand.
authors.forename: David
authors.initials: D
authors.lastname: Kim
authors.affiliation: Department of Endocrinology, Waitemata District Health Board, New Zealand.
authors.forename: Denise
authors.initials: D
authors.lastname: Mackenzie
authors.affiliation: Department of General Medicine, Waitemata District Health Board, New Zealand.
authors.forename: Rick
authors.initials: R
authors.lastname: Cutfield
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003695:Delivery of Health Care / Q000458:organization & administration; D005260:Female; D050723:Fractures, Bone / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009520:New Zealand; D058866:Osteoporotic Fractures / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control; D055502:Secondary Prevention / Q000458:organization & administration*
chemical_list: D050071:Bone Density Conservation Agents